1,608 reports of this reaction
3.2% of all HALOPERIDOL LACTATE reports
#3 most reported adverse reaction
NEUROLEPTIC MALIGNANT SYNDROME is the #3 most commonly reported adverse reaction for HALOPERIDOL LACTATE, manufactured by Fresenius Kabi USA, LLC. There are 1,608 FDA adverse event reports linking HALOPERIDOL LACTATE to NEUROLEPTIC MALIGNANT SYNDROME. This represents approximately 3.2% of all 50,066 adverse event reports for this drug.
Patients taking HALOPERIDOL LACTATE who experience neuroleptic malignant syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROLEPTIC MALIGNANT SYNDROME is moderately reported among HALOPERIDOL LACTATE users, representing a notable but not dominant share of adverse events.
In addition to neuroleptic malignant syndrome, the following adverse reactions have been reported for HALOPERIDOL LACTATE:
The following drugs have also been linked to neuroleptic malignant syndrome in FDA adverse event reports:
NEUROLEPTIC MALIGNANT SYNDROME has been reported as an adverse event in 1,608 FDA reports for HALOPERIDOL LACTATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROLEPTIC MALIGNANT SYNDROME accounts for approximately 3.2% of all adverse event reports for HALOPERIDOL LACTATE, making it one of the most commonly reported side effect.
If you experience neuroleptic malignant syndrome while taking HALOPERIDOL LACTATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.